| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/01/2006 | US20060115537 First nanoparticle of poly-gamma -glutamic acid/polylactide block copolymer and ganciclovir conjugated with galactosamine and second enhanced permeability nanoparticle of the block copolymer, endothelial cell-specific promoter, and (herpes-simplex-virus)-(thymidine kinase) gene constructed plasmid |
| 06/01/2006 | US20060115534 Process for the manufacture of powderous preparations of fat-soluble substances |
| 06/01/2006 | US20060115533 Pharmaceutical compositions |
| 06/01/2006 | US20060115530 Gastric acid secretion inhibiting composition |
| 06/01/2006 | US20060115528 Rapidly disintegrating tablet |
| 06/01/2006 | US20060115527 Controlled release preparation |
| 06/01/2006 | US20060115526 Venlafaxine compositions comprising pellets with double layer coating |
| 06/01/2006 | US20060115525 Pharmaceutical compositions |
| 06/01/2006 | US20060115522 Pharmaceutical composition |
| 06/01/2006 | US20060115520 Fluid application device and method |
| 06/01/2006 | US20060115518 Liquid seasoning |
| 06/01/2006 | US20060115517 Liquid seasoning |
| 06/01/2006 | US20060115513 Derivatized poly(ester amide) as a biobeneficial coating |
| 06/01/2006 | US20060115503 Composition, system and method for treatment of skin |
| 06/01/2006 | US20060115502 Cosmetic composition based on cirsimarin |
| 06/01/2006 | US20060115501 Homogeneously Formulating microdosed active principles |
| 06/01/2006 | US20060115500 Ophthalmic ointment composition comprising a drug, an ointment base and a solubilizing/dispersing agent |
| 06/01/2006 | US20060115492 Pharmaceutical composition and health food comprising extract of Phellinus sp. PL3 or phellinsin a isolated from the same as an effective component for prevention and treatment of cardiovascular disease |
| 06/01/2006 | US20060115480 Disease treatment via antimicrobial peptide inhibitors |
| 06/01/2006 | US20060115453 Methods and compositions for treating cellular proliferative diseases |
| 06/01/2006 | US20060115451 Modified cytokines for use in cancer therapy |
| 06/01/2006 | US20060115450 Polyalkylene glycol derivative and modified bio-related substance |
| 06/01/2006 | US20060115449 Bioabsorbable, biobeneficial, tyrosine-based polymers for use in drug eluting stent coatings |
| 06/01/2006 | US20060115448 Amphiphilic polynorbornene derivatives and methods of using the same |
| 06/01/2006 | US20060115432 Mixing a lactose fraction with small particle size with a carrier lactose contains amorphous lactose, exposing lactose mixture to a relative humidity of 85 % at a temp. from 20-40 degree C., then relative humidity of less than 20% at a temp.70 degree C. so that a modified lactose mixture is produced |
| 06/01/2006 | US20060115424 Combination therapy of oxaliplatin and radioactively doped particles treating cancer |
| 06/01/2006 | US20060113968 Novel benzonaphthyridines |
| 06/01/2006 | DE19901687B4 Opioide Analgetika mit kontrollierter Wirkstofffreisetzung Opioid analgesics controlled release |
| 06/01/2006 | DE102004057645A1 New substituted pteridine compounds, useful as phosphodiesterase 4 inhibitors for treating e.g. inflammatory diseases, cancer, asthma, ulcerative colitis, depression and schizophrenia |
| 06/01/2006 | DE102004057618A1 Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen Substituted pteridines for the treatment of inflammatory diseases |
| 06/01/2006 | DE102004057303A1 Stabile Kristallmodifikationen von DOTAP Chlorid Stable crystal modifications of DOTAP chloride |
| 06/01/2006 | DE102004057195A1 Kristalline Modifikationen von Crystalline modifications of N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon and / or salts thereof |
| 06/01/2006 | DE102004057171A1 Verwendung von Trimethylarsin als Verbindung mit organoleptischen Eigenschaften Using trimethyl as a compound with organoleptic properties |
| 06/01/2006 | DE102004056727A1 Kupfer-Melphalan und Kupfer-Tegafur als Antitumormittel Copper and copper-melphalan tegafur as an antitumor agent |
| 06/01/2006 | DE102004056659A1 New pharmaceutical composition comprising an oligonucleotide that is adapted to target nucleic acids encoding CD40, useful for preventing or treating an inflammatory, immune or autoimmune disorder |
| 06/01/2006 | CA2596194A1 Capsaicinoid gel formulation and uses thereof |
| 06/01/2006 | CA2595305A1 2-alcoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof |
| 06/01/2006 | CA2590349A1 Potentiators of glutamate receptors |
| 06/01/2006 | CA2589561A1 Treatment of neurodegenerative diseases by the use of laptm4a |
| 06/01/2006 | CA2589468A1 Process for preparing novel crystalline forms of (2s)-1-[[(7r)-7-(3,4-dichlorophenyl)-4,7-dihydro-5-methylpyrazolo[1,5]pyrimidine-6-yl]carbonyl]-2-(4-fluorophenyl) pyrrolidine, novel stable forms produced therein and formulations |
| 06/01/2006 | CA2589439A1 Modulators of muscarinic receptors |
| 06/01/2006 | CA2589438A1 Treatment of inflammatory bowel disease |
| 06/01/2006 | CA2589322A1 Dibenzyl amine compounds and derivatives |
| 06/01/2006 | CA2589318A1 Inhibitors of biotin protein ligase |
| 06/01/2006 | CA2589289A1 Use of (-)-1-(benzofuran-2-yl)-2-propylaminopentane to treat substance dependence |
| 06/01/2006 | CA2589285A1 Use of phospholipids for wound healing |
| 06/01/2006 | CA2589265A1 Dosage regimen of an s1p receptor agonist |
| 06/01/2006 | CA2589261A1 Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy |
| 06/01/2006 | CA2589258A1 N- [ (3s)- pyrrolidin-3-yl]- benzamide derivatives as monoamine re-uptake inhibitors |
| 06/01/2006 | CA2589250A1 Diazepine oxazolidinones as antibacterial agents |
| 06/01/2006 | CA2589242A1 Solid formulations of liquid biologically active agents |
| 06/01/2006 | CA2589237A1 (s)-(-)-1-(4-fluoroisoquinolin-5-yl)sulfonyl-2-methyl-1,4homopiperazine hydrochloride dihydrate |
| 06/01/2006 | CA2589209A1 Substituted pteridines for treating inflammatory diseases |
| 06/01/2006 | CA2589200A1 Formulations of pyridoxal -5'-phosphate and methods of preparation |
| 06/01/2006 | CA2589167A1 Extended release pharmaceutical composition of celecoxib |
| 06/01/2006 | CA2589085A1 Cathepsin cysteine protease inhibitors |
| 06/01/2006 | CA2589079A1 Nsaid compositions exhibiting clinical superiority |
| 06/01/2006 | CA2588881A1 Potentiators of glutamate receptors |
| 06/01/2006 | CA2588818A1 Athletic ability enhancing composition |
| 06/01/2006 | CA2588812A1 Therapeutic pyrazolo[3,4-b] pyridines and indazoles |
| 06/01/2006 | CA2588773A1 4-phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
| 06/01/2006 | CA2588713A1 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors |
| 06/01/2006 | CA2588599A1 2,3,4-substituted-cyclopentanones as therapeutic agents |
| 06/01/2006 | CA2588597A1 Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury |
| 06/01/2006 | CA2588558A1 Jnk inhibitors for treatment of cns injury |
| 06/01/2006 | CA2588449A1 An implant for intraocular drug delivery |
| 06/01/2006 | CA2588434A1 Copper melphalan and copper tegafur used as anti-tumoral agents |
| 06/01/2006 | CA2588412A1 2alpha-methyl-19-nor-1alpha-hydroxy-homopregnacalciferol and its uses |
| 06/01/2006 | CA2588406A1 2-.alpha.-methyl and 2-.beta.-methyl analogs of 19,26,27-trinor-(20s-1.alpha.-hydroxyvitamin d3 and their uses |
| 06/01/2006 | CA2588401A1 17,20(z)-dehydro vitamin d analogs and their uses |
| 06/01/2006 | CA2588399A1 2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol and its uses |
| 06/01/2006 | CA2588396A1 17,20(e)-dehydro vitamin d analogs and their uses |
| 06/01/2006 | CA2588293A1 Rasagiline orally disintegrating compositions |
| 06/01/2006 | CA2588060A1 2-methylene-19-nor-(20s)-1alpha-hydroxy-trishomopregnacalciferol |
| 06/01/2006 | CA2588036A1 Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
| 06/01/2006 | CA2587926A1 Bicyclic inhibitors or rho kinase |
| 06/01/2006 | CA2587894A1 Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases |
| 06/01/2006 | CA2587888A1 Novel 4-aminopiperidine derivatives as plasmepsin ii inhibitors |
| 06/01/2006 | CA2587860A1 Chroman compounds |
| 06/01/2006 | CA2587853A1 Gonadotropin releasing hormone receptor antagonists |
| 06/01/2006 | CA2587448A1 A method of administering anti-angiogenic agents and a method of treating disease using same |
| 06/01/2006 | CA2587256A1 Macrocyclic aminopyridyl beta-secretase inhibitors for the treatment of alzheimer's disease |
| 06/01/2006 | CA2587210A1 Tubulin binding anti cancer agents and prodrugs thereof |
| 06/01/2006 | CA2587207A1 Niacin receptor agonists, compositions containing such compounds and methods of treatment |
| 06/01/2006 | CA2587178A1 Novel 4-arylamino pyridone derivatives as mek inhibitors for the treatment of hyperproliferative disorders |
| 06/01/2006 | CA2587141A1 Octahydropyrrolo[3,4-c]pyrrole derivatives |
| 06/01/2006 | CA2587140A1 A combination of n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an anti-mitotic agent for the treatment of cancer |
| 06/01/2006 | CA2586883A1 Piperidinyl piperidine tachykinin receptor antagonists |
| 06/01/2006 | CA2586815A1 A composition comprising at least 3 different diols |
| 06/01/2006 | CA2586605A1 Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors |
| 06/01/2006 | CA2586553A1 Nasal sprayer containing a formulation with olopatadine |
| 06/01/2006 | CA2586443A1 5-hydroxy-benzothiazole derivatives having beta-2-adrenoreceptor agonist activity |
| 06/01/2006 | CA2586421A1 Pyridoxal-5-phosphate and stent for the treatment and prevention of atherosclerosis and restenosis |
| 06/01/2006 | CA2585990A1 Bengamides with a substituted caprolactame cycle, method for the preparation thereof, compositions containing them and use thereof |
| 06/01/2006 | CA2585857A1 Isoxazoline-indole derivatives with an improved antipsychotic and anxiolytic activity |
| 06/01/2006 | CA2584646A1 Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels |
| 06/01/2006 | CA2584427A1 Triple natural polymer viscoelastic composition |
| 06/01/2006 | CA2583315A1 Method and composition for enhancing anti-angiogenic therapy |
| 06/01/2006 | CA2582207A1 Inhalation medicament containing an anticholinesterase drug, salmeterol and a steroid selected from the ciclesonide or mometasone furoate group |
| 06/01/2006 | CA2582153A1 Inhalation medicament containing a novel anticholinesterase drug, formoterol and a steroid |